Rob's Avatar

Rob

@bulmani.bsky.social

Data Scientist working in the UK in the education sector - interest in health, especially Lp(a) research, due to being in the 20% with high Lp(a)

21 Followers  |  56 Following  |  30 Posts  |  Joined: 17.11.2024  |  1.7472

Latest posts by bulmani.bsky.social on Bluesky

Preview
Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials - PubMed Among available LLTs, PCSK9mAbs, inclisiran, CETPi, and niacin significantly decreased Lp(a) levels. Further research is necessary to understand whether this effect would translate into a clinically r...

A quick meta analysis of current lipid management therapies effect on LP(a) #lpa levels, and a call for more research on their effects on MACE/CVD outcomes pubmed.ncbi.nlm.nih.gov/40618457/

10.07.2025 13:09 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Lipoprotein(a) and recurrent atherosclerotic cardiovascular events: the US Family Heart Database AbstractBackground and Aims. Higher levels of lipoprotein(a) drive increasing risk of atherosclerotic cardiovascular disease (ASCVD) in otherwise healthy i

Large study on LP(a) #lpa levels, likelihood of ASCVD events and impact of LDL lowering on events - thank you @familyheartfdn.bsky.social much to take in academic.oup.com/eurheartj/ad...

11.05.2025 08:20 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Validate User

Excellent large study on the increased risk of ASCVD with increasing levels of LP(a) #lpa with evidence of mitigation by aggressive LDL lowering treatment, in particular with PCSK9 inhibitors academic.oup.com/eurheartj/ad...

07.05.2025 17:57 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Elevated lipoprotein(a) is not linked to coronary artery calcification incidence or progression AbstractAims. Lipoprotein(a) [Lp(a)] is a genetically determined, independent risk factor for atherosclerotic cardiovascular disease. However, its role in

An interesting study into CAC progression and associations with different levels of LP(a) which showed that LP(a) levels are not associated with CAC progress. Quite a powerful study with over 41,000 subjects #lpa academic.oup.com/eurjpc/advan...

05.04.2025 12:54 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
ALPACA: Single Injection of Novel Lepodisiran Reduces Lp(a) Concentration - American College of Cardiology

Lepodisiran, Eli Lily's (phase 2 trial results for a) LP(a) lowering drug ALPACA trial results show a 94% reductions in LP(a) #lpa 500+ days on with 2 injection split times process shows high reduction remains. Shows promise as a once a year shot treatment www.acc.org/Latest-in-Ca...

31.03.2025 07:17 โ€” ๐Ÿ‘ 3    ๐Ÿ” 2    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Lp(a) The hidden enemy? with Alberto Lorenzatti, MD YouTube video by MonteHeart Lectures

A great watch and summarisation of LP(a) from Alberto Lorenzatti via the excellent @monteheart.bsky.social lectures youtube.com/live/q1ziJBr...

29.03.2025 18:47 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
There is a linear negative correlation between lipoprotein(a) and non-alcoholic fatty liver disease - Scientific Reports Scientific Reports - There is a linear negative correlation between lipoprotein(a) and non-alcoholic fatty liver disease

Interesting piece of research, that indicates that higher levels of LP(a) are associated with less prevalence of NAFLD alongside other markers (e.g. hypertension) #lpa www.nature.com/articles/s41...

13.03.2025 08:10 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Impact of diabetes on risk of major adverse cardiovascular events associated with lipoprotein(a) levels in patients with established atherosclerotic cardiovascular disease AbstractAims. Lipoprotein(a) [Lp(a)] is an emerging risk factor for major adverse cardiovascular events (MACE). However, evidence on MACE risk according to

Among atherosclerotic patients with and without T2DM, elevated Lp(a) level was significantly associated with a higher risk of MACE. Compared to those without T2DM, the patients with T2DM showed an excess MACE risk #lpa both risks need treatment especially when combo academic.oup.com/eurjpc/advan...

13.03.2025 07:53 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
What Is Calcific Aortic Stenosis?

What Is Calcific Aortic Stenosis?

This JAMA Patient Page describes the risk factors, symptoms, diagnosis, and management of calcific aortic stenosis, which involves progressive narrowing and stiffening of the aortic valve. https://ja.ma/41xOEJr

27.02.2025 21:00 โ€” ๐Ÿ‘ 13    ๐Ÿ” 3    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Living with Elevated Lipoprotein(a) Levels: The Experiences of Patients and Caregivers Elevated lipoprotein(a) (Lp[a]) is an inherited condition that increases cardiovascular disease (CVD) risk, independent of other factors, such as low-density lipoprotein C. Few attempts have been m...

Very poignant for me this paper, on a week where I have been rejected for preventative advice and support from NHS specialists. The outcome - the same (even though this is US data), a lack of knowledge about LP(a) and poor support from health care #LPA www.tandfonline.com/doi/full/10....

23.02.2025 17:49 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

Treatment (US) recommendation graph in relation to the combination of high LP(a) #lpa levels and increasing CAC score. The combination of high LP(a) and high CAC score is a significant risk marker for CVD and should instigate a prompt response and activity www.researchgate.net/publication/...

15.02.2025 09:39 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
CTX-320 by CRISPR Therapeutics for Atherosclerosis: Likelihood of Approval CTX-320 is under clinical development by CRISPR Therapeutics and currently in Phase I for Atherosclerosis.

CRISPR tech lowering LP(a) #lpa 90% lowering with highest does, at least up to a year and counting www.pharmaceutical-technology.com/data-insight...

13.02.2025 07:41 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Lp(a) Clinical Guidance

This is a CVD calculator that I use when I get my blood results. It has a 2nd part once you press the calculate risk button to input your LP(a) levels and plots a new risk line. There is an option to plot a 3rd line against reductions of LDL-C & BP #lpa www.lpaclinicalguidance.com?fbclid=IwZXh...

09.02.2025 09:48 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

#lpa

08.02.2025 18:24 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Traditional risk factors, optimal cardiovascular health, and elevated lipoprotein(a) AbstractAims. To assess the association of traditional risk factor burden and Lifeโ€™s Simple 7 (LS7) score with incident atherosclerotic cardiovascular dise

Back to November 24 for this research - output conclusions that managing ASCVD risk via LS7 score assessment irrespective of LP(a) level showed a reduction of ASCVD development academic.oup.com/eurjpc/advan...

08.02.2025 18:23 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Post image

LP(a) HORIZON outputs from Phase 3 trial confirmed as 2026 (was first scheduled for 2025), an event lead assessment, this will depend on the number of total events, so could move again, events depending #lpa here hopefull

02.02.2025 18:12 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors onย Lipoprotein(a): A Meta-Analysis and Meta-Regression of Randomized Controlled Trials Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk.The authors examined the effect of monoclonal antibody proโ€ฆ

Meta analysis of PCSK9 inhibitors in LP(a) levels in those with high #lpa shows average of 27% reductions in LP(a) - calls for more analysis of whether the reductions resulted in better health outcomes and reductions of CVD events www.sciencedirect.com/science/arti...

30.01.2025 22:19 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Supine Blood Pressure and Risk of Cardiovascular Disease and Mortality This cohort study investigates the association of supine hypertension with cardiovascular disease and mortality in middle-aged adults.

Examination of supine hypertension and CHD outcomes in @jama.com Really interesting insight, given technology in this space is getting better for 24 hour monitoring, this data and that tech, could a) save a lot lives b) improve the health of many jamanetwork.com/journals/jam...

27.01.2025 11:57 โ€” ๐Ÿ‘ 1    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature Lipoprotein(a) [Lp(a)] is a well-established causal risk factor for cardiovascular diseases (CVDs), as reported by multiple Mendelian randomization studies and large epidemiological studies. When elev...

For a more detailed examination of LP(a) #lpa and LP(a) interaction with other lipids this is an excellent article www.mdpi.com/2218-273X/15...

26.01.2025 10:23 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
High Lp(a) Levels Harmful in Patients With and Without ASCVD (UPDATED) The threshold for increased risk differed, though, with only the highest Lp(a) levels conferring risk in secondary prevention.

I have this article locked in my archive of LP(a) articles, it is an easy read on the subject and again emphasizes the need for more research and data www.tctmd.com/news/high-lp...

26.01.2025 08:35 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Lipoprotein(a) and Cardiovascular Disease Risk Factors | Nature Research Intelligence Learn how Nature Research Intelligence gives you complete, forward-looking and trustworthy research insights to guide your research strategy.

Reasonable summary from 'Nature' on LP(a) good to get the profile on the subject matter and a readable introduction to the lipoprotein and further encouragement to people to get their levels checked with future treatments in the pipeline www.nature.com/research-int...

25.01.2025 09:24 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Preview
New Drugs Offer Hope for People With High Lipoprotein(a) Cholesterol There is no approved treatment for high lipoprotein(a), but five drugs are in development, and last fall, two of them moved a step closer to consideration by the FDA.

A good summary of the new LP(a) lowering medical trials, plus some individual stories and commentary on those trials and the people involved - hope remains www.webmd.com/cholesterol-...

24.01.2025 08:19 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

Great results from Phase 2 trial on Zerlasiran - providing hope that 2 jabs a year = significant reduction of Lp(a) Lipoprotein a, and safely. Plus added bonus of moderate ApoB reductions (see tables)

21.01.2025 16:20 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Prevalence of Lp(a) in a real-world Portuguese cohort: implications for cardiovascular risk assessment - Lipids in Health and Disease Background Cardiovascular disease (CVD) is a major cause of mortality worldwide, necessitating more refined strategies for risk assessment. Recently, lipoprotein(a) [Lp(a)] has gained attention for it...

High Lp(a) levels among those with ASCVD than proportional large cohort in a Portuguese population - emphasizing the need for people to get this measure checked. My own observation that the general 28.7% with high levels was higher than expected (20%) lipidworld.biomedcentral.com/articles/10....

21.01.2025 09:46 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

Has it reduced or increased your Lp(a) at all?

30.11.2024 23:13 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0

3/ Link to 'Life's Simple 7 Calculator': www.soapnote.org/cardiovascul...

30.11.2024 21:19 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

2/ They provide a very useful description:
"Participants without clinical ASCVD who achieved an optimal LS7 score had ASCVD risk reduction regardless of Lp(a) level. These results emphasize the importance of a healthy lifestyle and ASCVD risk factor control among individuals with elevated Lp(a)."

30.11.2024 21:17 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Preview
Traditional Risk Factors, Optimal Cardiovascular Health, and Elevated Lipoprotein(a) AbstractAims. To assess the association of traditional risk factor burden and Lifeโ€™s Simple 7 (LS7) score with incident atherosclerotic cardiovascular dise

An interesting piece of research in the European Journal of Preventive Cardiology, assessing the association of risk factors, the 'Life's Simple 7' score with incident ASCVD across variable Lp(a) levels.
academic.oup.com/eurjpc/advan...
#Lpa #lipoproteinlittlea

30.11.2024 21:12 โ€” ๐Ÿ‘ 0    ๐Ÿ” 2    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Preview
Association of cardiorespiratory fitness with dementia risk across different levels of genetic predisposition: a large community-based longitudinal study Objective We aimed to investigate the association of cardiorespiratory fitness (CRF) with cognitive function and dementia risk, taking genetic predisposition for dementia into account. Methods Within...

More research showing the benefits of exercise with regards to delaying the onset of dementia #dementia in the British Journal of Sports Medicine bjsm.bmj.com/content/earl...

20.11.2024 07:39 โ€” ๐Ÿ‘ 1    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission The 2024 update of the Lancet Commission on dementia provides new hopeful evidence about dementia prevention, intervention, and care. As people live longer, the number of people who live with dementia...

Interesting Lancet update regarding Dementia prevention www.thelancet.com/journals/lan...

18.11.2024 19:49 โ€” ๐Ÿ‘ 0    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

@bulmani is following 20 prominent accounts